10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2019 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 27, 2020) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Revenues | $ 51,750 | 53,647 | 52,546 |
| Costs and expenses: | |||
| Cost of sales | 10,219 | 11,248 [1] | 11,228 |
| Selling, informational and administrative expenses | 14,350 | 14,455 | 14,804 |
| Research and development expenses | 8,650 | 8,006 | 7,683 |
| Amortization of intangible assets | 4,610 | 4,893 | 4,758 |
| Restructuring charges and certain acquisition-related costs | 747 | 1,044 | 351 |
| (Gain) on completion of Consumer Healthcare JV transaction | (8,086) | 0 | 0 |
| Other (income)/deductionsnet | 3,578 | 2,116 | 1,416 |
| Income from continuing operations before provision/(benefit) for taxes on income | 17,682 | 11,885 [2] | 12,305 |
| Provision/(benefit) for taxes on income | 1,384 | 706 | (9,049) |
| Income from continuing operations | 16,298 [3] | 11,179 | 21,353 |
| Discontinued operations: | |||
| Income from discontinued operationsnet of tax | 4 | 10 | (1) |
| Gain on disposal of discontinued operationsnet of tax | 0 | 0 | 3 |
| Discontinued operationsnet of tax | 4 | 10 | 2 |
| Net income before allocation to noncontrolling interests | 16,302 | 11,188 | 21,355 |
| Less: Net income attributable to noncontrolling interests | 29 | 36 | 47 |
| Net income attributable to Pfizer Inc. | 16,273 | 11,153 | 21,308 |
| Earnings per common sharebasic: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 2.92 | 1.90 | 3.57 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | 0.00 | 0.00 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 2.92 | 1.90 | 3.57 |
| Earnings per common sharediluted: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 2.87 | 1.86 | 3.52 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | 0.00 | 0.00 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 2.87 | 1.87 | 3.52 |
| Weighted-average sharesbasic | 5,569 | 5,872 | 5,970 |
| Weighted-average sharesdiluted | 5,675 | 5,977 | 6,058 |
| [3] Amounts may not add due to rounding. | |||
| [1] Exclusive of amortization of intangible assets, except as disclosed in Note 1L. | |||
| [2] 2019 v. 2018The domestic income in 2019 versus domestic loss in 2018 was mainly related to the completion of the Consumer Healthcare joint venture transaction with GSK as well as lower certain asset impairments, partially offset by reduced Lyrica revenues in the U.S., higher business and legal entity alignment costs as well as increased costs related to certain legal matters. The decrease in the international income was primarily related to higher certain asset impairments as well as the write off of asse | |||
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |